top of page

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for more

  • Nov 12, 2025
  • 1 min read

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.




Coverage brought to you by


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page